SeaSpine to Report Second Quarter 2021 Financial Results on August 2, 2021
SeaSpine Holdings Corporation (NASDAQ: SPNE) will release its second quarter financial results on August 2, 2021, after market close. A conference call will follow at 2:00 PM PT / 5:00 PM ET, accessible via phone and webcast. SeaSpine specializes in surgical solutions for spinal disorders, offering a wide range of orthobiologics and spinal implants. The company markets its products in the U.S. and approximately 30 countries, focusing on enhancing bone fusion rates and supporting various spinal procedures.
- Scheduled release of second quarter financial results could provide fresh insights into company performance.
- Broad portfolio of orthobiologics and spinal implants positions SeaSpine favorably in the medical technology market.
- None.
CARLSBAD, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release second quarter financial results after the close of trading on Monday, August 2, 2021. Members of the Company’s management team will host a corresponding conference call and webcast beginning at 2:00 pm PT / 5:00 pm ET.
Individuals interested in listening to the conference call may do so by dialing (877) 418-4766 for domestic callers or (614) 385-1253 for international callers, using Conference ID: 1257053. To listen to a live webcast, please visit the Investors section of the SeaSpine website at: www.seaspine.com.
About SeaSpine
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions, as well as a market leading surgical navigation system, to meet the varying combinations of products and enabling technologies that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in orthobiologic sciences, as well as spinal implants and software product development, allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.
Investor Relations Contact
Leigh Salvo
(415) 937-5402
ir@seaspine.com
FAQ
When will SeaSpine Holdings Corporation release its second quarter financial results for 2021?
What time is the SeaSpine financial results conference call scheduled?
How can I listen to the SeaSpine Holdings Corporation conference call?
What products does SeaSpine Holdings Corporation offer?
